The firms will screen compounds from natural sources for activity against gene variants linked to chronic diseases.

In his first term, pharmaceutical companies took the "most favored nation" policy to court over the White House's effort to slash costs for patients.

After seeing promising results in preclinical studies, the firm hopes to begin Phase I trials shortly after getting IND clearance.